Taiwan Stands Firm on Hepatitis B Vaccination for Newborns

Taiwan will continue its universal vaccination program for newborns against hepatitis B, despite recent changes to recommendations from US health authorities. The Centers for Disease Control (CDC) in Taiwan confirmed this decision following a vote by the US Advisory Committee on Immunization Practices (ACIP), which opted to limit hepatitis B vaccinations to infants at higher risk.

The ACIP voted 8-3 to recommend hepatitis B shots only for newborns whose mothers are either positive for the virus or whose status is unknown. For infants born to mothers who test negative, the ACIP suggested that parents make individualized decisions regarding the vaccine. The first dose would not be administered before two months of age for those who do not receive the birth dose.

In response, CDC spokesman Lin Min-cheng stated that Taiwan’s policy will remain unchanged. This decision was made after consultations with members of Taiwan’s ACIP, reflecting the country’s unique healthcare landscape.

Historical Context and Current Statistics

Hepatitis B has historically been a significant public health issue in Taiwan, primarily transmitted from mothers to their children. To combat this, Taiwan introduced its universal vaccination program in July 1986. By November 1992, the vaccination schedule for newborns was established as three doses administered at “zero, one, and six months” after birth. Since May 2011, the first dose has been recommended to be given within 24 hours of birth.

Taiwan has achieved impressive vaccination coverage rates. In 2022, the first-dose coverage rate for infants reached 93.1 percent, while the second and third doses were administered at rates of 98.9 percent and 97.7 percent, respectively. Lin explained that the first-dose coverage is slightly lower due to some newborns requiring emergency care or being born with low body weight, preventing them from receiving the vaccine immediately. In such cases, vaccinations are provided once the infants are stable.

The universal vaccination policy has proven effective, decreasing the hepatitis B carrier rate among children to less than 0.8 percent, a stark decline from the previous rate of 10.5 percent before the policy was implemented.

Implications of the Policy Decision

The CDC’s commitment to maintaining a universal hepatitis B vaccination program stems from the ongoing prevalence of the virus among those born before this policy was adopted. This group continues to face a substantial disease burden, including serious conditions like liver cirrhosis and liver cancer, which differ significantly from trends observed in the United States.

The CDC’s action aligns with Taiwan’s public health goals, aiming to protect its population from the long-term consequences of hepatitis B. The differing vaccination strategies between Taiwan and the United States highlight the importance of tailoring public health policies to meet the specific needs and circumstances of each country.

As global health policies evolve, Taiwan’s steadfast approach to hepatitis B vaccinations underscores its commitment to safeguarding the health of its youngest citizens.